SLNSW-Trastuzumab emtansine versus capecitabine plus la...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Full title: Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Author/creator: Diéras, Véronique, Dr, Miles, David, Prof, Verma, Sunil, MD, Pegram, Mark, Prof, Welslau, Manfred, MD, Baselga, José, MD, Krop, Ian E, MD, Blackwell, Kim, Prof, Hoersch, Silke, MSc, Xu, Jin, PhD, Green, Marjorie, MD, Gianni, Luca, MD.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    Share

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Full title

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Author / Creator

    Diéras, Véronique, Dr ; Miles, David, Prof ; Verma, Sunil, MD ; Pegram, Mark, Prof ; Welslau, Manfred, MD ; Baselga, José, MD ; Krop, Ian E, MD ; Blackwell, Kim, Prof ; Hoersch, Silke, MSc ; Xu, Jin, PhD ; Green, Marjorie, MD ; Gianni, Luca, MD

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2017, Vol.18 (6), p.732-742

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Acute myeloid leukemia Adult Aged Aged, 80 and over Analysis Anemia Anemia - chemically induced Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aspartate aminotransferase Aspartate Aminotransferases - blood Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms, Male - chemistry Breast Neoplasms, Male - drug therapy Breast Neoplasms, Male - pathology Bridged-Ring Compounds - administration & dosage Cancer therapies Capecitabine - administration & dosage Capecitabine - adverse effects Care and treatment Chemotherapy Coronary artery Cytotoxicity Diarrhea Diarrhea - chemically induced Disease-Free Survival Encephalopathy Epidermal growth factor ErbB-2 protein Female Hand-Foot Syndrome - etiology Heart diseases Hematology, Oncology and Palliative Medicine Humans Immunotherapy Lapatinib Leukemia Male Maytansine - adverse effects Maytansine - analogs & derivatives Maytansine - therapeutic use Medical prognosis Metabolic disorders Metastases Metastasis Middle Aged Monoclonal antibodies Motivation Neutropenia Patient outcomes Quinazolines - administration & dosage Quinazolines - adverse effects Receptor, ErbB-2 - analysis Response Evaluation Criteria in Solid Tumors Retreatment Sepsis Studies Survival Survival analysis Survival Rate Targeted cancer therapy Taxoids - administration & dosage Thrombocytopenia Thrombocytopenia - chemically induced Trastuzumab Trastuzumab - administration & dosage Tumors Vomiting Vomiting - chemically induced Young Adult

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531181

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections